Edition:
United States

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,169.25INR
23 Feb 2018
Change (% chg)

Rs47.95 (+2.26%)
Prev Close
Rs2,121.30
Open
Rs2,125.00
Day's High
Rs2,183.65
Day's Low
Rs2,125.00
Volume
25,863
Avg. Vol
53,121
52-wk High
Rs2,948.00
52-wk Low
Rs1,901.65

Chart for

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.05
Market Cap(Mil.): Rs359,499.59
Shares Outstanding(Mil.): 165.89
Dividend: 20.00
Yield (%): 0.92

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-Dr.Reddy's Laboratories Says Amended Complaint w.r.t U.S. Class Action Lawsuit Filed

* W.R.T U.S. CLASS ACTION LAWSUIT, AMENDED COMPLAINT FILED BY PLAINTIFF WHERE CHAIRMAN, COO AND U.S. UNIT ADDED AS DEFENDANTS Source text - http://bit.ly/2CvdcnN Further company coverage:

Feb 19 2018

BRIEF-Dr.Reddy's Lab Announces Launch Of Tetrabenazine Tablets In U.S. Market

* SAYS ANNOUNCEMENT OF LAUNCH OF TETRABENAZINE TABLETS IN U.S. MARKET Source text - http://bit.ly/2GH4t5d Further company coverage:

Feb 02 2018

India's Dr. Reddy's third-quarter profit tumbles, hit by U.S. pricing pressure

Indian generic drugmaker Dr. Reddy's Laboratories Ltd said quarterly net profit slumped nearly 40 percent, its third consecutive quarter of declines as pricing pressures in the United States hit sales.

Jan 25 2018

UPDATE 1-India's Dr. Reddy's Q3 profit tumbles, hit by U.S. pricing pressure

* Europe generics revenue down 7 pct (Adds revenue drops for N. American, European generics business)

Jan 25 2018

BRIEF-India's Dr.Reddy's Laboratories Dec-Qtr Consol Net PAT Falls 38.5 Pct

* DEC QUARTER CONSOL NET PROFIT AFTER TAX 3.03 BILLION RUPEES VERSUS PROFIT OF 4.92 BILLION RUPEES LAST YEAR

Jan 25 2018

BRIEF-Dr.Reddy's Laboratories Launches Melphalan Hydrochloride Injection In U.S.

* SAYS LAUNCH OF MELPHALAN HYDROCHLORIDE FOR INJECTION IN U.S. MARKET Source text - http://bit.ly/2C8souU Further company coverage:

Dec 26 2017

BRIEF-Dr. Reddy's Reaches Settlement With U.S. Government Regarding Compliance With Consumer Product Safety Act

* DR. REDDY'S ANNOUNCES IT HAS REACHED A SETTLEMENT WITH US GOVERNMENT REGARDING COMPANY'S COMPLIANCE WITH CONSUMER PRODUCT SAFETY ACT

Dec 19 2017

BRIEF-Dr.Reddy's Labs Gets EIR From U.S. FDA ‍​For Facility In Hyderabad

* SAYS GETS EIR FROM U.S. FDA ‍​FOR CUSTOM PHARMA SERVICES FACILITY IN HYDERABAD Source text - http://bit.ly/2ANfrXj Further company coverage:

Dec 01 2017

BRIEF-Dr.Reddy's Labs Gets U.S. FDA Nod For Psoriasis Treatment

* SAYS CO, THROUGH UNIT, GETS NDA NOD FOR PSORIASIS TREATMENT Source text: http://bit.ly/2kd95cA Further company coverage:

Nov 30 2017

BRIEF-Dr.Reddy's Laboratories gets German Regulator's Nod For CAPA Plan

* SAYS GERMAN REGULATOR PERMITTED PRODUCTION TO START AGAIN FROM FACILITY FOR EU MARKET‍​

Nov 30 2017

Earnings vs. Estimates